OCT 05, 2016 02:24 PM PDT

Kidney Cancer Drug Repurposed to Treat Other Cancers

WRITTEN BY: Xuan Pham
A drug that’s approved for the treatment of kidney cancer could find renewed purpose against other cancer types too. After scrutinizing hundreds of drugs for common cell signaling pathways, researcher in Norway found that the same drug that fights kidney cancer – axitini – could also be effective aginst breast, prostate, and colorectal cancers.


Perhaps one of the best outcomes for pharmacologists is the discovery that common, pre-existing drugs could treat new conditions. This is the impetus behind the growing field of research known as “drug repurposing.”
 
Because so much money and time are spent for every drug that’s on the market, finding new uses for these commercially available drug effectively reduces the burden on the industry and patients could have more options sooner rather than later.
 
The team at Norway honed in on axitini only after screening an impressive 500 known compounds. They were looking for drugs that could block growth signals that allow cancer cells to proliferate without control. In this screen, axitini stood out as having an alternate mechanism of action that was previously unknown.
 
Axitini is a known tyrosine kinase inhibitor – it blocks the activation of many other downstream signals in the cell. Pertaining to kidney cancer, axitini stops angiogenesis – the process by which tumors grow new blood vessels.
 
But the research team found that axitini also blocks a signaling pathway known as Wnt signaling. Mutations in this pathway are associated with various conditions, including breast and prostate cancer, which have prompted research into finding suitable Wnt inhibitors. It appears then, that the Norway scientists may have found such an inhibitor. And the best part, we already know that axitini is safe to use in people.
 

When a pre-existing drug shows promise for a new disease, things tend to move much faster. Because toxicity and pharmacokinetics have been established, the time for it to reach patients should be cut dramatically. This could means years shaved off of moving a drug through the pipeline to get to the market.
 
The technique of scanning old drugs for new pathways may also have proved more fruitful, as the team hinted that there could be 3 to 4 more candidates to be on the look out for in the future.

Additional sources: MNT, University of Bergen
About the Author
  • I am a human geneticist, passionate about telling stories to make science more engaging and approachable. Find more of my writing at the Hopkins BioMedical Odyssey blog and at TheGeneTwist.com.
You May Also Like
JUL 30, 2018
Cancer
JUL 30, 2018
Challenges Coming to a Cancer Diagnosis in the UK
England's NHS Cancer Patient Experience Survey shows some cancers take longer for GPs to recognize....
AUG 07, 2018
Cancer
AUG 07, 2018
Renal Cell Carcinoma and Myelodysplastic Syndrome Show Epigenetic Association
DNA methylation patterns in renal cell carcinoma (RCC) have a strong association with myelodysplastic syndrome DNA hypermethylation later in life....
SEP 15, 2018
Clinical & Molecular DX
SEP 15, 2018
Cancer & Anoikis: A Match Not Made in Heaven
Anoikis have always been intimately entwined with cancer, henceforth the quest to seek how they came to be as such....
OCT 29, 2018
Immunology
OCT 29, 2018
Escape of the Tumor Cell
Tumor cells in breast cancer have proven to evade the immune responses utilizing actin cytoskeleton...
NOV 24, 2018
Drug Discovery
NOV 24, 2018
New Anti-Malarial Drug Target in Cancer
For decades, anti-malaria drugs--known as Chloroquines, have used to treat cancer. But the role in repurposing these drugs for slowing tumor growth have ne...
DEC 03, 2018
Cancer
DEC 03, 2018
Using bubbly nano-particles for chemotherapy delivery
We have all heard about the harsh side effects of chemotherapy that could be so difficult leading to stopping treatment. The reason behind those side effects is that chemotherapy drugs do tar...
Loading Comments...